PARP Inhibitors Market
Trends in the PARP Inhibitors Market 2017-2027
Cancer is the leading cause of death worldwide with 8.2 million cancer related deaths in 2012 estimated by World Health Organization ( WHO ). PARP Inhibitors are the drugs , which inhibit the enzyme called poly ADP ribose polymerase ( PARP ). PARP inhibitors developed for treating several diseases , the most important one is cancer . As several types of cancers rely on PARP than regular cells , which makes it attractive target for treating cancers . These PARP inhibitors used to treat subset of ovarian cancer . Currently only PARP inhibitors approved in the market is Lynparza from AstraZeneca and several PARP inhibitors are in late stage pipeline which are showing promising results in the recent released clinical trials data . The first PARP inhibitor from AstraZeneca approved in late 2014 and market witnessed significant gain in 2015 . PARP inhibitors mainly indicated in few set of patients based molecular diagnostics . Several positive end points for these drugs are prolonged Progression Free Survival ( PFS ) and over survival rates .
PARP inhibitors Market : Drivers and Restraints
PARP inhibitors market is driven by promising pipeline products which are showing positive results in recent times and increasing awareness among healthcare professionals and patients . Apart from aforementioned drivers , PARP inhibitors market is driven by improved safety profile of these drugs compared to cell-therapy drugs and increased US FDA approval for these drugs and rising incidences of cancer over the forecast period .
© 2015 Future Market Insights , All Rights Reserved 4